

Summary of status of development and availability of A(H7) candidate vaccine viruses*

* Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise indicated all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test.

[National or Regional control authorities approve the composition and formulation of vaccines used in each country.](#)

11 September 2012

Candidate vaccine viruses

Subtype	Parent virus	Clade	Candidate vaccine virus	Type of virus or reassortant	Developing Institute	Available from
H7N1	A/mallard/Netherlands/12/2000	Eurasian	NIBRG-63	Reverse genetics	NIBSC, UK	NIBSC, UK
H7N2	A/turkey/Virginia/4529/2002	American	IBCDC-5	Classical reassortant	CDC, USA	CDC, USA
	A/New York/107/2003	American	NIBRG-109	Reverse genetics	NIBSC, UK	NIBSC, UK
H7N3	A/Canada/rv444/2004	American	161984-B	Reverse genetics	ST. JUDE, USA CDC, USA	ST. JUDE, USA CDC, USA
	A/mallard/Netherlands/12/2000	Eurasian	NIBRG-60	Reverse genetics	NIBSC, UK	NIBSC, UK
H7N7	A/mallard/Netherlands/12/2000 and A/mallard/Netherlands/2/2000	Eurasian	IBCDC-1 [#]	Classical reassortant	CDC, USA	CDC, USA

[#]HA from A/mallard/Netherlands/12/2000 and NA from A/mallard/Netherlands/2/2000

Institutes and contact details for candidate vaccine virus orders and other information:

CDC: Centers for Disease Control and Prevention, USA: rvd6@cdc.gov

NIBSC: National Institute for Biological Standards and Control, UK: standards@nibsc.org

ST. JUDE: ST. Jude Children's Research Hospital, USA: richard.webby@stjude.org

For general enquiries, please contact gisrs-whohq@who.int

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to: <http://www.who.int/influenza/vaccines/virus/en/>